CEL-SCI Corp. (CVM)
2.15
-0.59
(-21.53%)
USD |
NYAM |
Oct 07, 15:22
CEL-SCI Net Income (Quarterly) : -5.668M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.668M |
| March 31, 2026 | -5.466M |
| December 31, 2025 | -5.469M |
| September 30, 2025 | -6.101M |
| June 30, 2025 | -5.665M |
| March 31, 2025 | -6.572M |
| December 31, 2024 | -7.073M |
| September 30, 2024 | -6.110M |
| June 30, 2024 | -6.857M |
| March 31, 2024 | -7.245M |
| December 31, 2023 | -6.710M |
| September 30, 2023 | -7.631M |
| June 30, 2023 | -8.367M |
| March 31, 2023 | -8.343M |
| December 31, 2022 | -7.854M |
| September 30, 2022 | -8.462M |
| June 30, 2022 | -9.633M |
| March 31, 2022 | -9.824M |
| December 31, 2021 | -8.783M |
| September 30, 2021 | -8.205M |
| June 30, 2021 | -8.938M |
| March 31, 2021 | -11.28M |
| December 31, 2020 | -7.937M |
| September 30, 2020 | -5.548M |
| June 30, 2020 | -10.28M |
| Date | Value |
|---|---|
| March 31, 2020 | -9.068M |
| December 31, 2019 | -5.531M |
| September 30, 2019 | -4.848M |
| June 30, 2019 | -12.08M |
| March 31, 2019 | -6.448M |
| December 31, 2018 | 1.246M |
| September 30, 2018 | -14.93M |
| June 30, 2018 | -6.015M |
| March 31, 2018 | -4.708M |
| December 31, 2017 | -6.188M |
| September 30, 2017 | -4.994M |
| June 30, 2017 | -4.464M |
| March 31, 2017 | -8.426M |
| December 31, 2016 | 3.521M |
| September 30, 2016 | -1.160M |
| June 30, 2016 | -3.862M |
| March 31, 2016 | -8.856M |
| December 31, 2015 | 2.333M |
| September 30, 2015 | -9.844M |
| June 30, 2015 | -4.429M |
| March 31, 2015 | -12.56M |
| December 31, 2014 | -7.845M |
| September 30, 2014 | -7.222M |
| June 30, 2014 | -2.444M |
| March 31, 2014 | -13.37M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
| Imunon, Inc. | -2.814M |
| Curis, Inc. | -8.581M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.668M |
| EPS Diluted (Quarterly) | -0.4678 |
| Enterprise Value | 49.56M |
| Earnings Yield | -120.1% |
| Normalized Earnings Yield | -120.19 |